Physician profile
Erann J Bulman
NPI 1841980869
$12,742.30
in general payments reported to CMS, 2019-2025
60 companies · $4,269 in 2025
The $4,269 reported for 2025 was more than what 98% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $3,101 · 2024: $5,373 · 2025: $4,269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Long Term Medical Supply Or Device Loan: $1,196 · Education: $642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,903.73 |
| Long Term Medical Supply Or Device Loan | $1,196.40 |
| Education | $642.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,064.57 | 2023-2025 | |
| Lilly USA, LLC | $807.36 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Janssen Biotech, INC. | $599.98 | 2024-2025 | Tecvayli, Darzalex, Erleada |
| Abbvie INC. | $591.43 | 2023-2025 | |
| Pfizer INC. | $587.70 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $579.66 | 2023-2025 | Calquence, Tagrisso, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $566.46 | 2023-2025 | Opdivo, Opdualag, Pomalyst |
| Celgene Corporation | $507.57 | 2023-2025 | Reblozyl, Pomalyst, Opdivo |
| Merck Sharp & Dohme LLC | $498.84 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Genentech USA, INC. | $481.97 | 2023-2025 | Itovebi, Phesgo, Perjeta |
| Regeneron Healthcare Solutions, INC. | $399.87 | 2023-2025 | Libtayo, Lynozyfic |
| Astellas Pharma US INC | $275.72 | 2023-2025 | Padcev, Xospata, Xtandi |
| Takeda Pharmaceuticals U.S.A., INC. | $270.24 | 2023-2025 | Ninlaro, Fruzaqla |
| Bayer Healthcare Pharmaceuticals INC. | $269.31 | 2023-2025 | |
| Incyte Corporation | $267.41 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $261.72 | 2023-2025 | Ojjaara, Jemperli, Blenrep |
| Gilead Sciences, INC. | $241.75 | 2023-2025 | Trodelvy |
| Eisai INC. | $235.88 | 2023-2025 | |
| Daiichi Sankyo INC. | $222.18 | 2023-2025 | Enhertu, Injectafer |
| Genzyme Corporation | $221.52 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $215.70 | 2023-2025 | Ultomiris |
| Iovance Biotherapeutics, INC. | $159.52 | 2025 | Amtagvi |
| Aveo Pharmaceuticals, INC. | $156.95 | 2023-2025 | Fotivda |
| Karyopharm Therapeutics INC. | $150.37 | 2023-2025 | Xpovio |
| Puma Biotechnology, INC. | $149.27 | 2023-2025 | Nerlynx |
| Deciphera Pharmaceuticals INC. | $148.26 | 2023-2025 | Qinlock, Romvimza |
| Genmab U.S., INC. | $144.27 | 2023-2025 | Epkinly |
| Array Biopharma INC | $130.26 | 2023-2025 | Lorbrena, Braftovi, Mektovi |
| Kite Pharma, INC. | $98.15 | 2023 | Yescarta |
| Exelixis INC. | $96.09 | 2024 | Cabometyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.04 | 2023-2025 | Gilotrif |
| Jazz Pharmaceuticals INC. | $82.79 | 2024-2025 | |
| Amgen INC. | $76.35 | 2023 | Lumakras, Nplate, Xgeva |
| Beigene USA, INC. | $74.62 | 2025 | Brukinsa, Tevimbra |
| Emd Serono, INC. | $74.38 | 2023-2025 | Bavencio |
| Sobi, INC | $74.06 | 2024-2025 | |
| Adc Therapeutics America, INC. | $69.84 | 2023-2025 | |
| Beone Medicines USA, INC. | $69.14 | 2025 | Brukinsa, Tevimbra |
| Novocure INC. | $68.05 | 2024-2025 | Optune Lua (Novottf-200t) |
| Morphosys, US INC. | $49.98 | 2023 | Monjuvi |
| Mirati Therapeutics, INC. | $49.58 | 2023-2024 | Krazati |
| Blueprint Medicines Corporation | $49.57 | 2023-2024 | Ayvakit |
| Geron Corporation | $48.58 | 2025 | Rytelo |
| Taiho Oncology, INC. | $42.62 | 2023-2025 | |
| Pharmacosmos Therapeutics INC. | $40.85 | 2024-2025 | Cosela, Monoferric |
| Rigel Pharmaceuticals, INC. | $37.99 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Janssen Scientific Affairs, LLC | $34.90 | 2024 | Talvey, Tecvayli, Darzalex |
| Caris Mpi, INC. | $33.26 | 2025 | Mi Cancer Seek |
| Myriad Genetic Laboratories, INC. | $32.26 | 2023-2024 | Precisetumor, Myrisk |
| Immunogen, INC. | $28.76 | 2023 | Elahere |
| Syndax Pharmaceuticals, INC. | $26.62 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $26.02 | 2023 | Imbruvica |
| Servier Pharmaceuticals LLC | $24.86 | 2025 | |
| Pharmaessentia USA Corporation | $24.35 | 2023 | Besremi |
| Springworks Therapeutics, INC. | $23.99 | 2024 | Ogsiveo |
| G1 Therapeutics, INC. | $22.30 | 2023 | Cosela |
| Tersera Therapeutics LLC | $20.86 | 2024 | Zoladex |
| Apellis Pharmaceuticals, INC. | $19.51 | 2023 | Empaveli |
| Verity Pharmaceuticals INC. | $19.07 | 2023 | Trelstar |
| Ipsen Biopharmaceuticals, INC | $13.12 | 2023 | Onivyde |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erann Bulman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.